Trial to Compare the Efficacy and Safety Of MW05 and PEG-rhG-CSF

Exclusion Criteria

• •1. History of other malignant tumors (skin basal cell carcinoma, skin squamous cell carcinoma and / or carcinoma in situ after radical resection can be included in the group after being cured for more than 5 years)
• •2. Primary hematological diseases, including but not limited to myelodysplastic syndrome, aplastic anemia, sickle cell anemia and other hematological diseases that affect bone marrow hematopoiesis.
• •3. With known central nervous system metastasis or suspected central nervous system metastasis based on clinical manifestations.
• •4. With previous history of bone marrow transplantation and / or stem cell transplantation.
• •5. Currently uncontrolled infections or have received systematic anti-infective therapy within 72 hours before randomization.
• •6. Serious chronic diseases of important organs such as kidney and liver.
• •7. Severe heart disease, including but not limited to:history of congestive heart failure (New York College of Cardiology \[NYHA\] II or higher heart disease)Angina pectoris that needs to be treated with anti-angina pectoris drugsUncontrollable hypertension (systolic blood pressure ≥ 180 mmHg and / or diastolic blood pressure ≥ 100 mmHg)Arrhythmias requiring drug treatment
• •8. Severe diabetes (such as fundus disease or diabetic foot), or blood sugar is still not well controlled after active treatment.
• •9. Surgery within 2 weeks before chemotherapy or radiotherapy within 4 weeks (except for patients whose physical condition has recovered and can accept the relevant procedures of this study, as determined by the researchers)
• •10. Adverse reactions from previous treatments failed to recover to CTCAE v5.0 score ≤ 1 (except for alopecia and other toxic reactions that researchers believe do not affect the safety of this chemotherapy)
• •11. According to the researchers, there are serious risks to the safety of patients or concomitant diseases that affect the completion of the study.
• •12. Participated in clinical trials of any other drugs within 4 weeks.
• •13. Received the same efficacy drugs(such as PEG-rhG-CSF or rhG-CSF, etc.) are still in 5 half-lives or within 28 days (whichever is shorter).
• •14. With allergic disease or allergic constitution, and who have previously been allergic to any drug or its components in this trial.
• •15. Active hepatitis B (HBsAg positive and HBV-DNA copy number greater than the normal limit) and / or active hepatitis C (hepatitis C virus antibody positive and HCV-RNA copy number greater than the normal limit) and / or human immunodeficiency virus antibody positive and / or Treponema pallidum antibody.
• •16. Drug abuse. history or drug abusers
• •17. Pregnant or lactating women
• •18. Who have been judged by the researchers to be unsuitable for selection or who are not suitable for other reasons